Aurobindo Pharma Limited has informed the Exchange regarding 'CuraTeQ Biologics receives approval for biosimilar Dyrupeg from UK s MHRA'.

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹1102.50

prior close

₹1117.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.5%+1.1% vs market

Pharmaceuticals peers, median of 150sector+0.9%+0.8% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.2

15m

-0.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7+0.5+1.1+0.9+0.8

Next day

+1.9+1.1+0.8+0.8+1.1

+2.0+1.5+0.6+1.5+0.5

+2.7+2.2+0.6+2.5+0.2

+3.1+2.0+1.1+2.3+0.7

+5.1+1.9+3.2+2.4+2.7

+8.0+2.1+5.9+3.2+4.8

15d

+4.6+2.2+2.4+5.3-0.7

+1.6-0.1+1.7+2.7-1.1

-3.2-0.4-2.8-1.5-1.7

-0.4-0.7+0.3-0.4+0.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has received marketing authorization from the UK's MHRA for Dyrupeg, a pegylated filgrastim biosimilar used in cancer care. This is CuraTeQ's third biosimilar approved by MHRA, following Bevqolva in December 2024 and Zefylti in May 2025. The product had earlier received EU approval in April 2025, making the UK approval a follow-on market access win. The approvals signal a maturing biosimilar pipeline from Aurobindo's biologics arm.

Likely market impact

Positively builds Aurobindo's biologics franchise and opens a new revenue stream in the UK, a hard-currency market. No immediate financial guidance is given, so near-term impact is sentiment-driven and dependent on subsequent commercial uptake.